Literature DB >> 10871310

Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan.

S S Shetty1, D DelGrande.   

Abstract

The effects of valsartan and other nonpeptide angiotensin II type 1 (AT(1)) receptor blockers on the prejunctional actions of angiotensin II were investigated in the isolated left atria of rat. Norepinephrine stores in rat atria were loaded with [(3)H]norepinephrine, and neuronal norepinephrine release was deduced from the radioactivity efflux. Angiotensin II (10(-9) to 10(-6) M) produced concentration-dependent enhancement of the electrical stimulation-induced efflux of [(3)H]norepinephrine from the preparation. Pretreatment of tissues with valsartan, irbesartan, eprosartan, or losartan (10(-8) to 10(-6) M) produced concentration-dependent inhibitions of the stimulation-induced efflux of radioactivity observed in the presence of angiotensin II (10(-7) M). The AT(1) receptor blockers did not decrease the "basal stimulation-induced overflow of radioactivity but rather selectively inhibited the angiotensin II-mediated augmentation of the response. Regression analyses of the inhibition of the angiotensin II-mediated response by valsartan, irbesartan, eprosartan, and losartan revealed corresponding log IC(50) values (log M, with 95% confidence intervals) of -7.78 (-8.19, -7.51), -7.65 (-8.02, -7.40), -7.12 (-7. 37, -6.86), and -6.75 (-7.00, -6.40), indicating that the IC(50) values for valsartan and irbesartan are significantly lower than those for eprosartan and losartan. Thus, valsartan is a potent inhibitor of the prejunctional facilitatory effect of angiotensin II on the release of norepinephrine from peripheral sympathetic nerves. This implies that the therapeutic domain of valsartan may be extended to include pathophysiological conditions such as congestive heart failure wherein prejunctional angiotensin II receptors apparently play a significant role. Whether the high potency of valsartan translates into a significant clinical advantage relative to the other agents tested remains to be ascertained.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871310

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Eprosartan: a review of its use in the management of hypertension.

Authors:  Gayle W Robins; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Angiotensin-converting enzyme gates brain circuit-specific plasticity via an endogenous opioid.

Authors:  Brian H Trieu; Bailey C Remmers; Carlee Toddes; Dieter D Brandner; Emilia M Lefevre; Adrina Kocharian; Cassandra L Retzlaff; Rachel M Dick; Mohammed A Mashal; Elysia A Gauthier; Wei Xie; Ying Zhang; Swati S More; Patrick E Rothwell
Journal:  Science       Date:  2022-02-24       Impact factor: 63.714

3.  A pharmacological differentiation between postjunctional (AT1A) and prejunctional (AT1B) angiotensin II receptors in the rabbit aorta.

Authors:  Serafim Guimarães; Catarina Carneiro; Fernando Brandão; Helder Pinheiro; António Albino-Teixeira; Daniel Moura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-23       Impact factor: 3.000

4.  Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans.

Authors:  Henrik Vase; Thomas G Lauridsen; Jesper N Bech; Erling B Pedersen
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

5.  Development of baroreflex function and hind limb vascular reactivity in the horse fetus.

Authors:  Susie J O'Connor; Jenny C Ousey; David S Gardner; Abigail L Fowden; Dino A Giussani
Journal:  J Physiol       Date:  2006-02-09       Impact factor: 5.182

Review 6.  The effect of angiotensin receptor blockers for preventing atrial fibrillation.

Authors:  Kristian Wachtell; Richard B Devereux; And Paulette A Lyle
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

Review 7.  Clinical profile of eprosartan: a different angiotensin II receptor blocker.

Authors:  P J Blankestijn; H Rupp
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2008-10

8.  Interaction between the Renin-Angiotensin System and Enteric Neurotransmission Contributes to Colonic Dysmotility in the TNBS-Induced Model of Colitis.

Authors:  Mariana Ferreira-Duarte; Tiago Rodrigues-Pinto; Teresa Sousa; Miguel A Faria; Maria Sofia Rocha; Daniela Menezes-Pinto; Marisa Esteves-Monteiro; Fernando Magro; Patrícia Dias-Pereira; Margarida Duarte-Araújo; Manuela Morato
Journal:  Int J Mol Sci       Date:  2021-05-03       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.